JP2004502690A - 酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物 - Google Patents

酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物 Download PDF

Info

Publication number: JP2004502690A
Authority: JP; Japan
Prior art keywords: alkyl; dione; benzyl; purine; dihydro
Prior art date: 2000-07-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2002507812A

Other languages

English (en)

Japanese (ja)

Other versions

JP2004502690A5 (2

Inventor

カンストルプ，アンデルス　ベンツ

クリスチャンセン，リセ　ブロウン

ルンドベック，ヤネ　マリエ

サムス，クリスチャン　ケー．

クリスチャンセン，マリット

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-04

Filing date

2001-07-04

Publication date

2004-01-29

2001-07-04 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2004-01-29 Publication of JP2004502690A publication Critical patent/JP2004502690A/ja

2005-02-03 Publication of JP2004502690A5 publication Critical patent/JP2004502690A5/ja

Status Withdrawn legal-status Critical Current

Links

108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title abstract description 27
239000003112 inhibitor Substances 0.000 title description 10
150000002391 heterocyclic compounds Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 205
-1 cycloheteroalkyl Chemical group 0.000 claims description 252
125000003118 aryl group Chemical group 0.000 claims description 162
125000000217 alkyl group Chemical group 0.000 claims description 157
125000001072 heteroaryl group Chemical group 0.000 claims description 132
238000000034 method Methods 0.000 claims description 129
125000000753 cycloalkyl group Chemical group 0.000 claims description 95
229910052736 halogen Inorganic materials 0.000 claims description 75
150000002367 halogens Chemical class 0.000 claims description 75
125000003342 alkenyl group Chemical group 0.000 claims description 73
125000000304 alkynyl group Chemical group 0.000 claims description 64
125000004093 cyano group Chemical group *C#N 0.000 claims description 50
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 48
125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 46
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 45
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
125000003545 alkoxy group Chemical group 0.000 claims description 36
125000006481 2-iodobenzyl group Chemical group [H]C1=C([H])C(I)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 33
125000004104 aryloxy group Chemical group 0.000 claims description 26
125000005553 heteroaryloxy group Chemical group 0.000 claims description 26
150000003839 salts Chemical class 0.000 claims description 26
125000003302 alkenyloxy group Chemical group 0.000 claims description 21
125000005133 alkynyloxy group Chemical group 0.000 claims description 21
229910052799 carbon Inorganic materials 0.000 claims description 21
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
125000003003 spiro group Chemical group 0.000 claims description 15
125000004432 carbon atom Chemical group C* 0.000 claims description 14
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
ARAFEULRMHFMDE-UHFFFAOYSA-N 1,3-oxazolidine-2,5-dione Chemical compound O=C1CNC(=O)O1 ARAFEULRMHFMDE-UHFFFAOYSA-N 0.000 claims description 8
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 8
229940091173 hydantoin Drugs 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
SJSOFNCYXJUNBT-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 claims description 6
YPBLCMLMLKMJGR-UHFFFAOYSA-N 3,7-dibenzyl-8-(1,4-diazepan-1-yl)-1-propylpurine-2,6-dione Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 YPBLCMLMLKMJGR-UHFFFAOYSA-N 0.000 claims description 6
OSWQQKHGTFZUND-UHFFFAOYSA-N 7-benzyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 OSWQQKHGTFZUND-UHFFFAOYSA-N 0.000 claims description 6
125000003710 aryl alkyl group Chemical group 0.000 claims description 6
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
WQACCWREPPVZEE-UHFFFAOYSA-N 3-benzyl-7-[(2-iodophenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound IC1=CC=CC=C1CN1C(C(=O)NC(=O)N2CC=3C=CC=CC=3)=C2N=C1N1CCNCC1 WQACCWREPPVZEE-UHFFFAOYSA-N 0.000 claims description 5
QGTFEGHGPMCJRF-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-3-methyl-7-[(2-phenylphenyl)methyl]purine-2,6-dione Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 QGTFEGHGPMCJRF-UHFFFAOYSA-N 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
125000005842 heteroatom Chemical group 0.000 claims description 5
230000005764 inhibitory process Effects 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
JGRYCVHBJUYLBF-UHFFFAOYSA-N 3,7-dibenzyl-8-(1,4-diazepan-1-yl)purine-2,6-dione Chemical compound C1CCNCCN1C1=NC=2N(CC=3C=CC=CC=3)C(=O)NC(=O)C=2N1CC1=CC=CC=C1 JGRYCVHBJUYLBF-UHFFFAOYSA-N 0.000 claims description 4
TXBOFWTZGOSLJG-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 TXBOFWTZGOSLJG-UHFFFAOYSA-N 0.000 claims description 4
FURSBRLQELDELR-UHFFFAOYSA-N 7-benzyl-8-(6-hydroxy-1,4-diazepan-1-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC(O)C1 FURSBRLQELDELR-UHFFFAOYSA-N 0.000 claims description 4
RRLWFBZULYMFIM-UHFFFAOYSA-N 7-benzyl-8-[6-(hydroxymethyl)-1,4-diazepan-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC(CO)C1 RRLWFBZULYMFIM-UHFFFAOYSA-N 0.000 claims description 4
PXFNLWLXKDYPPC-UHFFFAOYSA-N 1,3,7-tribenzyl-8-(1,4-diazepan-1-yl)purine-2,6-dione Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 PXFNLWLXKDYPPC-UHFFFAOYSA-N 0.000 claims description 3
RAIXEGWBDXUGCZ-UHFFFAOYSA-N 1,3,7-tribenzyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 RAIXEGWBDXUGCZ-UHFFFAOYSA-N 0.000 claims description 3
BEHAXAWRLPRXQA-UHFFFAOYSA-N 1,3-dimethyl-7-(1-phenylethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CNCCN1C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1C(C)C1=CC=CC=C1 BEHAXAWRLPRXQA-UHFFFAOYSA-N 0.000 claims description 3
TUINWARGYHZQDA-UHFFFAOYSA-N 1,3-dimethyl-7-(2-oxo-2-pyrrolidin-1-ylethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CCCN1C(=O)CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 TUINWARGYHZQDA-UHFFFAOYSA-N 0.000 claims description 3
SHERAUCGTHRFCU-UHFFFAOYSA-N 1,3-dimethyl-7-(2-oxopropyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CC(=O)C)C=1N1CCNCC1 SHERAUCGTHRFCU-UHFFFAOYSA-N 0.000 claims description 3
RFOQPGZBMDFBEQ-UHFFFAOYSA-N 1,3-dimethyl-7-(naphthalen-1-ylmethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC2=CC=CC=C2C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 RFOQPGZBMDFBEQ-UHFFFAOYSA-N 0.000 claims description 3
AUDGXLGJGSACKY-UHFFFAOYSA-N 1,3-dimethyl-7-(naphthalen-2-ylmethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C2C=CC=CC2=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 AUDGXLGJGSACKY-UHFFFAOYSA-N 0.000 claims description 3
ZWWQXABLXZRLHQ-UHFFFAOYSA-N 1,3-dimethyl-7-[(2-phenylphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 ZWWQXABLXZRLHQ-UHFFFAOYSA-N 0.000 claims description 3
NMRONBQQOFJQMI-UHFFFAOYSA-N 1,3-dimethyl-7-[(4-methylphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1=CC(C)=CC=C1CN1C(C(=O)N(C)C(=O)N2C)=C2N=C1N1CCNCC1 NMRONBQQOFJQMI-UHFFFAOYSA-N 0.000 claims description 3
LFPQTPGHRXOWQE-UHFFFAOYSA-N 1,3-dimethyl-7-[(4-methylsulfonylphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 LFPQTPGHRXOWQE-UHFFFAOYSA-N 0.000 claims description 3
YNWZYDDOWBGNJA-UHFFFAOYSA-N 1,3-dimethyl-7-[(4-phenylmethoxyphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 YNWZYDDOWBGNJA-UHFFFAOYSA-N 0.000 claims description 3
LPEVDFICEYSMRJ-UHFFFAOYSA-N 1,3-dimethyl-7-[(4-phenylphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 LPEVDFICEYSMRJ-UHFFFAOYSA-N 0.000 claims description 3
CAJKDPDHZJIDTN-UHFFFAOYSA-N 1,3-dimethyl-8-piperazin-1-yl-7-[[2-(trifluoromethoxy)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=CC=C(OC(F)(F)F)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 CAJKDPDHZJIDTN-UHFFFAOYSA-N 0.000 claims description 3
VCPMPUPMTXJKOP-UHFFFAOYSA-N 1,3-dimethyl-8-piperazin-1-yl-7-[[2-(trifluoromethyl)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=CC=C(C(F)(F)F)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 VCPMPUPMTXJKOP-UHFFFAOYSA-N 0.000 claims description 3
XPLGFGQUGAMMFE-UHFFFAOYSA-N 1,3-dimethyl-8-piperazin-1-yl-7-[[2-(trifluoromethylsulfanyl)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=CC=C(SC(F)(F)F)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 XPLGFGQUGAMMFE-UHFFFAOYSA-N 0.000 claims description 3
MUWCAZJOWUNWBF-UHFFFAOYSA-N 1,3-dimethyl-8-piperazin-1-yl-7-[[4-(thiadiazol-4-yl)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=C(C=2N=NSC=2)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 MUWCAZJOWUNWBF-UHFFFAOYSA-N 0.000 claims description 3
OLBSWCPPNRDGHV-UHFFFAOYSA-N 1,3-dimethyl-8-piperazin-1-yl-7-[[4-(trifluoromethoxy)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=C(OC(F)(F)F)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 OLBSWCPPNRDGHV-UHFFFAOYSA-N 0.000 claims description 3
DOTJJCPEGRLPKG-UHFFFAOYSA-N 1,3-dimethyl-8-piperazin-1-yl-7-[[4-(trifluoromethyl)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=C(C(F)(F)F)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 DOTJJCPEGRLPKG-UHFFFAOYSA-N 0.000 claims description 3
XOBBNSWCWZBJEQ-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC3OCCO3)C(=O)N(C)C=2N=C1N1CCNCC1 XOBBNSWCWZBJEQ-UHFFFAOYSA-N 0.000 claims description 3
NPJXQLXQBXSUSV-UHFFFAOYSA-N 1-(2,3-dihydroxypropyl)-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC(O)CO)C(=O)N(C)C=2N=C1N1CCNCC1 NPJXQLXQBXSUSV-UHFFFAOYSA-N 0.000 claims description 3
HLWCVFLZGYBBLF-UHFFFAOYSA-N 1-(2-ethoxyethyl)-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOCC)C(=O)N(C)C=2N=C1N1CCNCC1 HLWCVFLZGYBBLF-UHFFFAOYSA-N 0.000 claims description 3
HVDNFWUPVJSVCF-UHFFFAOYSA-N 1-(3-hydroxy-2-methylpropyl)-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC(CO)C)C(=O)N(C)C=2N=C1N1CCNCC1 HVDNFWUPVJSVCF-UHFFFAOYSA-N 0.000 claims description 3
JTHDTFWKDJQQNT-UHFFFAOYSA-N 1-(3-hydroxypropyl)-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1N1CCNCC1 JTHDTFWKDJQQNT-UHFFFAOYSA-N 0.000 claims description 3
URZNPYLSKANYBX-UHFFFAOYSA-N 1-[(3,5-dimethoxyphenyl)methyl]-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound COC1=CC(OC)=CC(CN2C(C=3N(CC=4C(=CC=CC=4)I)C(N4CCNCC4)=NC=3N(C)C2=O)=O)=C1 URZNPYLSKANYBX-UHFFFAOYSA-N 0.000 claims description 3
YJXVYRTXEWNXBU-UHFFFAOYSA-N 1-[2-(1,3-dioxan-2-yl)ethyl]-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCC3OCCCO3)C(=O)N(C)C=2N=C1N1CCNCC1 YJXVYRTXEWNXBU-UHFFFAOYSA-N 0.000 claims description 3
LFRBEBHGMGBNJA-UHFFFAOYSA-N 1-[2-(1,3-dioxolan-2-yl)ethyl]-7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCC3OCCO3)C(=O)N(C)C=2N=C1N1CCNCC1 LFRBEBHGMGBNJA-UHFFFAOYSA-N 0.000 claims description 3
IXKJEHCNDGRQIE-UHFFFAOYSA-N 2-[(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 IXKJEHCNDGRQIE-UHFFFAOYSA-N 0.000 claims description 3
UHQKILMVZSXOKY-UHFFFAOYSA-N 2-[(3-benzyl-2,6-dioxo-8-piperazin-1-yl-1-propylpurin-7-yl)methyl]benzonitrile Chemical compound C1=2N=C(N3CCNCC3)N(CC=3C(=CC=CC=3)C#N)C=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 UHQKILMVZSXOKY-UHFFFAOYSA-N 0.000 claims description 3
FQNCNHMYMXLKJN-UHFFFAOYSA-N 2-[(3-benzyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]benzonitrile Chemical compound C1CNCCN1C1=NC=2N(CC=3C=CC=CC=3)C(=O)NC(=O)C=2N1CC1=CC=CC=C1C#N FQNCNHMYMXLKJN-UHFFFAOYSA-N 0.000 claims description 3
DAMIFCSDOSBGPT-UHFFFAOYSA-N 2-[(3-methyl-2,6-dioxo-8-piperazin-1-yl-1-propylpurin-7-yl)methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1N1CCNCC1 DAMIFCSDOSBGPT-UHFFFAOYSA-N 0.000 claims description 3
NTHAWSJFDJMXJT-UHFFFAOYSA-N 2-[3,7-dibenzyl-8-(1,4-diazepan-1-yl)-2,6-dioxopurin-1-yl]-n,n-diethylacetamide Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(=O)N(CC)CC)C(=O)N1CC1=CC=CC=C1 NTHAWSJFDJMXJT-UHFFFAOYSA-N 0.000 claims description 3
ABDBLPAYLUKXBO-UHFFFAOYSA-N 2-[7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-2,6-dioxopurin-1-yl]acetonitrile Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CC#N)C(=O)N(C)C=2N=C1N1CCCNCC1 ABDBLPAYLUKXBO-UHFFFAOYSA-N 0.000 claims description 3
SGWVFVNUZSMLQJ-UHFFFAOYSA-N 2-[[3-benzyl-8-(1,4-diazepan-1-yl)-2,6-dioxo-1-propylpurin-7-yl]methyl]benzonitrile Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C(=CC=CC=3)C#N)C=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 SGWVFVNUZSMLQJ-UHFFFAOYSA-N 0.000 claims description 3
IEXAFRUCIULFQM-UHFFFAOYSA-N 2-[[3-benzyl-8-(1,4-diazepan-1-yl)-2,6-dioxopurin-7-yl]methyl]benzonitrile Chemical compound C1CCNCCN1C1=NC=2N(CC=3C=CC=CC=3)C(=O)NC(=O)C=2N1CC1=CC=CC=C1C#N IEXAFRUCIULFQM-UHFFFAOYSA-N 0.000 claims description 3
XRIBCIOFSQNYHZ-UHFFFAOYSA-N 2-[[8-(1,4-diazepan-1-yl)-1,3-dimethyl-2,6-dioxopurin-7-yl]methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 XRIBCIOFSQNYHZ-UHFFFAOYSA-N 0.000 claims description 3
ARDVRBRYSMFVPO-UHFFFAOYSA-N 2-[[8-(1,4-diazepan-1-yl)-3-methyl-2,6-dioxo-1-propylpurin-7-yl]methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1N1CCCNCC1 ARDVRBRYSMFVPO-UHFFFAOYSA-N 0.000 claims description 3
125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
IWPZKOJSYQZABD-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Natural products COC1=CC(OC)=CC(C(O)=O)=C1 IWPZKOJSYQZABD-UHFFFAOYSA-N 0.000 claims description 3
IUTLQECRZFAVCC-UHFFFAOYSA-N 3,7-dibenzyl-1-(2-hydroxyethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCO)C(=O)N1CC1=CC=CC=C1 IUTLQECRZFAVCC-UHFFFAOYSA-N 0.000 claims description 3
GPJWBLBMRFZPJJ-UHFFFAOYSA-N 3,7-dibenzyl-8-(1,4-diazepan-1-yl)-1-(2-hydroxyethyl)purine-2,6-dione Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCO)C(=O)N1CC1=CC=CC=C1 GPJWBLBMRFZPJJ-UHFFFAOYSA-N 0.000 claims description 3
IHMUGTWSLVOXMM-UHFFFAOYSA-N 3,7-dibenzyl-8-piperazin-1-yl-1-propylpurine-2,6-dione Chemical compound C1=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 IHMUGTWSLVOXMM-UHFFFAOYSA-N 0.000 claims description 3
HUWDKUCQBWWICY-UHFFFAOYSA-N 3,7-dibenzyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CNCCN1C1=NC=2N(CC=3C=CC=CC=3)C(=O)NC(=O)C=2N1CC1=CC=CC=C1 HUWDKUCQBWWICY-UHFFFAOYSA-N 0.000 claims description 3
ULAHPACZETZFAE-UHFFFAOYSA-N 3-[(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]benzonitrile Chemical compound C=1C=CC(C#N)=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 ULAHPACZETZFAE-UHFFFAOYSA-N 0.000 claims description 3
HVPCSXHMLGSQSS-UHFFFAOYSA-N 3-benzyl-7-(2-phenylethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CNCCN1C1=NC=2N(CC=3C=CC=CC=3)C(=O)NC(=O)C=2N1CCC1=CC=CC=C1 HVPCSXHMLGSQSS-UHFFFAOYSA-N 0.000 claims description 3
SDZUNFWODRWSPN-UHFFFAOYSA-N 3-benzyl-8-(1,4-diazepan-1-yl)-1-(2-ethoxyethyl)-7-[(2-iodophenyl)methyl]purine-2,6-dione Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C(=CC=CC=3)I)C=2C(=O)N(CCOCC)C(=O)N1CC1=CC=CC=C1 SDZUNFWODRWSPN-UHFFFAOYSA-N 0.000 claims description 3
FITOMBDCAHKKEV-UHFFFAOYSA-N 3-benzyl-8-(1,4-diazepan-1-yl)-1-(3-hydroxypropyl)-7-[(2-iodophenyl)methyl]purine-2,6-dione Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C(=CC=CC=3)I)C=2C(=O)N(CCCO)C(=O)N1CC1=CC=CC=C1 FITOMBDCAHKKEV-UHFFFAOYSA-N 0.000 claims description 3
IKXOFFFGTPLULJ-UHFFFAOYSA-N 3-benzyl-8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-1-propylpurine-2,6-dione Chemical compound C1=2N=C(N3CCNCCC3)N(CC=3C(=CC=CC=3)I)C=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 IKXOFFFGTPLULJ-UHFFFAOYSA-N 0.000 claims description 3
NOWIILLDHUPAOI-UHFFFAOYSA-N 3-benzyl-8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]purine-2,6-dione Chemical compound IC1=CC=CC=C1CN1C(C(=O)NC(=O)N2CC=3C=CC=CC=3)=C2N=C1N1CCNCCC1 NOWIILLDHUPAOI-UHFFFAOYSA-N 0.000 claims description 3
NFKOOVKWNUMEQY-UHFFFAOYSA-N 3-benzyl-8-piperazin-1-yl-7-[[2-(trifluoromethyl)phenyl]methyl]purine-2,6-dione Chemical compound FC(F)(F)C1=CC=CC=C1CN1C(C(=O)NC(=O)N2CC=3C=CC=CC=3)=C2N=C1N1CCNCC1 NFKOOVKWNUMEQY-UHFFFAOYSA-N 0.000 claims description 3
OZJASCJKXWVJDK-UHFFFAOYSA-N 3-methyl-7-(1-phenylethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CNCCN1C1=NC=2N(C)C(=O)NC(=O)C=2N1C(C)C1=CC=CC=C1 OZJASCJKXWVJDK-UHFFFAOYSA-N 0.000 claims description 3
ZRSJKBZMIQCRAV-UHFFFAOYSA-N 3-methyl-7-(3-methylbutyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCC(C)C)C=1N1CCNCC1 ZRSJKBZMIQCRAV-UHFFFAOYSA-N 0.000 claims description 3
URWZRCBFOLIMBX-UHFFFAOYSA-N 3-methyl-7-(3-phenylpropyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CCCN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 URWZRCBFOLIMBX-UHFFFAOYSA-N 0.000 claims description 3
FHZBVCZOBHIKJB-UHFFFAOYSA-N 3-methyl-7-[(2-methyl-1,3-thiazol-4-yl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound S1C(C)=NC(CN2C=3C(=O)NC(=O)N(C)C=3N=C2N2CCNCC2)=C1 FHZBVCZOBHIKJB-UHFFFAOYSA-N 0.000 claims description 3
NCBQWTNHQFIYCS-UHFFFAOYSA-N 3-methyl-7-[(3-methylphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound CC1=CC=CC(CN2C=3C(=O)NC(=O)N(C)C=3N=C2N2CCNCC2)=C1 NCBQWTNHQFIYCS-UHFFFAOYSA-N 0.000 claims description 3
OUSLXRFGRYFMIR-UHFFFAOYSA-N 3-methyl-7-pentyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCCCC)C=1N1CCNCC1 OUSLXRFGRYFMIR-UHFFFAOYSA-N 0.000 claims description 3
UTGRHIJKSXXDBN-UHFFFAOYSA-N 3-methyl-8-piperazin-1-yl-1,7-dipropylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(CCC)C(=O)C=2N(CCC)C=1N1CCNCC1 UTGRHIJKSXXDBN-UHFFFAOYSA-N 0.000 claims description 3
PSTDNERGQHJGIB-UHFFFAOYSA-N 3-methyl-8-piperazin-1-yl-7-propylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCC)C=1N1CCNCC1 PSTDNERGQHJGIB-UHFFFAOYSA-N 0.000 claims description 3
125000006500 3-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC(F)(F)F)=C1[H])C([H])([H])* 0.000 claims description 3
MVRUYOHKQDONBC-UHFFFAOYSA-N 4-(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)butanenitrile Chemical compound N#CCCCN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 MVRUYOHKQDONBC-UHFFFAOYSA-N 0.000 claims description 3
FRWDQHBRKHYONF-HXUWFJFHSA-N 6-[[8-[(3r)-3-benzylpiperazin-1-yl]-1,3-dimethyl-2,6-dioxopurin-7-yl]methyl]pyridine-3-carbonitrile Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1N=CC(=CC=1)C#N)=O)C)C1=CC=CC=C1 FRWDQHBRKHYONF-HXUWFJFHSA-N 0.000 claims description 3
WNAQNKUVYWGXJY-UHFFFAOYSA-N 7-(cyclohexylmethyl)-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CCCCC1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 WNAQNKUVYWGXJY-UHFFFAOYSA-N 0.000 claims description 3
YLYLGNKNHCKNRS-UHFFFAOYSA-N 7-[(2,3-dimethoxyphenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound COC1=CC=CC(CN2C=3C(=O)N(C)C(=O)N(C)C=3N=C2N2CCNCC2)=C1OC YLYLGNKNHCKNRS-UHFFFAOYSA-N 0.000 claims description 3
NIVZGQOLOXPLPJ-UHFFFAOYSA-N 7-[(2,4-dichlorophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=C(Cl)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 NIVZGQOLOXPLPJ-UHFFFAOYSA-N 0.000 claims description 3
JOLRDKJWSNCHRR-UHFFFAOYSA-N 7-[(2-bromophenyl)methyl]-8-(1,4-diazepan-1-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=C(Br)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 JOLRDKJWSNCHRR-UHFFFAOYSA-N 0.000 claims description 3
SPQSMUBJSLJCEW-UHFFFAOYSA-N 7-[(2-bromophenyl)methyl]-8-(1,4-diazepan-1-yl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(Br)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 SPQSMUBJSLJCEW-UHFFFAOYSA-N 0.000 claims description 3
WMQWNGOCKCYSAY-UHFFFAOYSA-N 7-[(2-chlorophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(Cl)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 WMQWNGOCKCYSAY-UHFFFAOYSA-N 0.000 claims description 3
JBFDJSHNNKJSAF-UHFFFAOYSA-N 7-[(2-chlorophenyl)methyl]-8-(1,4-diazepan-1-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=C(Cl)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 JBFDJSHNNKJSAF-UHFFFAOYSA-N 0.000 claims description 3
BBWPIYLOSRGZMP-UHFFFAOYSA-N 7-[(2-chlorophenyl)methyl]-8-(1,4-diazepan-1-yl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(Cl)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 BBWPIYLOSRGZMP-UHFFFAOYSA-N 0.000 claims description 3
ZDBWAYPVJJLVKO-UHFFFAOYSA-N 7-[(2-fluoro-6-nitrophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound FC=1C=CC=C([N+]([O-])=O)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 ZDBWAYPVJJLVKO-UHFFFAOYSA-N 0.000 claims description 3
OQTJURQATCCKKL-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 OQTJURQATCCKKL-UHFFFAOYSA-N 0.000 claims description 3
NSCXITDZJATTGU-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-1-(2-methoxyethyl)-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOC)C(=O)N(C)C=2N=C1N1CCNCC1 NSCXITDZJATTGU-UHFFFAOYSA-N 0.000 claims description 3
BCJMJXVRYWGBFN-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-1-(2-phenoxyethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOC=3C=CC=CC=3)C(=O)N(C)C=2N=C1N1CCNCC1 BCJMJXVRYWGBFN-UHFFFAOYSA-N 0.000 claims description 3
QFGPYFWLXPBQIP-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-1-(2-phenylmethoxyethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOCC=3C=CC=CC=3)C(=O)N(C)C=2N=C1N1CCNCC1 QFGPYFWLXPBQIP-UHFFFAOYSA-N 0.000 claims description 3
DHKVFXHJILVMAO-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-1-(oxan-2-ylmethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC3OCCCC3)C(=O)N(C)C=2N=C1N1CCNCC1 DHKVFXHJILVMAO-UHFFFAOYSA-N 0.000 claims description 3
JLYQREMFFLYFIF-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-1-(oxolan-2-ylmethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC3OCCC3)C(=O)N(C)C=2N=C1N1CCNCC1 JLYQREMFFLYFIF-UHFFFAOYSA-N 0.000 claims description 3
UCZBSOLWLMJVJE-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-yl-1-propylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1N1CCNCC1 UCZBSOLWLMJVJE-UHFFFAOYSA-N 0.000 claims description 3
CYYCNDISYWTPJK-UHFFFAOYSA-N 7-[(3,4-dichlorophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(Cl)C(Cl)=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 CYYCNDISYWTPJK-UHFFFAOYSA-N 0.000 claims description 3
FIYVUQJPOVRHOW-UHFFFAOYSA-N 7-[(3-bromophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC(Br)=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 FIYVUQJPOVRHOW-UHFFFAOYSA-N 0.000 claims description 3
NUQFSJZWLOJBLL-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 NUQFSJZWLOJBLL-UHFFFAOYSA-N 0.000 claims description 3
RRNBOXVRQBNZGX-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(C(=O)N(C)C(=O)N2C)=C2N=C1N1CCNCC1 RRNBOXVRQBNZGX-UHFFFAOYSA-N 0.000 claims description 3
XLTDIXNGQNKIJS-UHFFFAOYSA-N 7-[(4-tert-butylphenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(C(C)(C)C)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 XLTDIXNGQNKIJS-UHFFFAOYSA-N 0.000 claims description 3
DDXUHHBMYLOMJQ-UHFFFAOYSA-N 7-[(5-chloro-2-nitrophenyl)methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C(Cl)=CC=C([N+]([O-])=O)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 DDXUHHBMYLOMJQ-UHFFFAOYSA-N 0.000 claims description 3
YOZCVGNKCHWWJJ-ONEGZZNKSA-N 7-[(e)-but-2-enyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(C/C=C/C)C=1N1CCNCC1 YOZCVGNKCHWWJJ-ONEGZZNKSA-N 0.000 claims description 3
WNVROUIPADYYDI-UHFFFAOYSA-N 7-[2-hydroxy-2-(4-nitrophenyl)ethyl]-3-methyl-8-piperazin-1-yl-8,9-dihydropurine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(C)C=2NC(N2CCNCC2)N1CC(O)C1=CC=C([N+]([O-])=O)C=C1 WNVROUIPADYYDI-UHFFFAOYSA-N 0.000 claims description 3
LRUXRWIHRNWCMG-UHFFFAOYSA-N 7-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1=CC(OC)=CC=C1OCC(O)CN1C(C(=O)NC(=O)N2C)=C2N=C1N1CCNCC1 LRUXRWIHRNWCMG-UHFFFAOYSA-N 0.000 claims description 3
FGLVRZOGQIYUNT-UHFFFAOYSA-N 7-[[2-(difluoromethoxy)phenyl]methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(OC(F)F)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 FGLVRZOGQIYUNT-UHFFFAOYSA-N 0.000 claims description 3
RRGCXOMYSQPOSN-UHFFFAOYSA-N 7-benzyl-1,3-dimethyl-8-(3-propan-2-ylpiperazin-1-yl)purine-2,6-dione Chemical compound C1CNC(C(C)C)CN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(C)C(=O)N2C RRGCXOMYSQPOSN-UHFFFAOYSA-N 0.000 claims description 3
VYJVCJURPANQIE-MRXNPFEDSA-N 7-benzyl-1,3-dimethyl-8-[(3r)-3-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]purine-2,6-dione Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CSC=N1 VYJVCJURPANQIE-MRXNPFEDSA-N 0.000 claims description 3
ABAABJIAXXUISM-LJQANCHMSA-N 7-benzyl-1,3-dimethyl-8-[(3r)-3-[(4-nitrophenyl)methyl]piperazin-1-yl]purine-2,6-dione Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CC=C([N+]([O-])=O)C=C1 ABAABJIAXXUISM-LJQANCHMSA-N 0.000 claims description 3
RRGCXOMYSQPOSN-INIZCTEOSA-N 7-benzyl-1,3-dimethyl-8-[(3r)-3-propan-2-ylpiperazin-1-yl]purine-2,6-dione Chemical compound C1CN[C@H](C(C)C)CN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(C)C(=O)N2C RRGCXOMYSQPOSN-INIZCTEOSA-N 0.000 claims description 3
ZKYFKZYTOZKYDQ-NRFANRHFSA-N 7-benzyl-1,3-dimethyl-8-[(3s)-3-(phenylmethoxymethyl)piperazin-1-yl]purine-2,6-dione Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)OCC1=CC=CC=C1 ZKYFKZYTOZKYDQ-NRFANRHFSA-N 0.000 claims description 3
RRGCXOMYSQPOSN-MRXNPFEDSA-N 7-benzyl-1,3-dimethyl-8-[(3s)-3-propan-2-ylpiperazin-1-yl]purine-2,6-dione Chemical compound C1CN[C@@H](C(C)C)CN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(C)C(=O)N2C RRGCXOMYSQPOSN-MRXNPFEDSA-N 0.000 claims description 3
XWJPFOQAUBQIPS-UHFFFAOYSA-N 7-benzyl-1,3-dimethyl-8-[3-(2-phenylethyl)piperazin-1-yl]purine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N(C1)CCNC1CCC1=CC=CC=C1 XWJPFOQAUBQIPS-UHFFFAOYSA-N 0.000 claims description 3
QFSMMXJBEBXTJP-UHFFFAOYSA-N 7-benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 QFSMMXJBEBXTJP-UHFFFAOYSA-N 0.000 claims description 3
YKXVBUBJYLKMOL-UHFFFAOYSA-N 7-benzyl-3-methyl-8-piperazin-1-yl-1-propylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1N1CCNCC1 YKXVBUBJYLKMOL-UHFFFAOYSA-N 0.000 claims description 3
JSWNZGOFKHAWGV-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 JSWNZGOFKHAWGV-UHFFFAOYSA-N 0.000 claims description 3
CNGJKAAPTBOPCF-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-1-(2-ethoxyethyl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCOCC)C(=O)N(C)C=2N=C1N1CCCNCC1 CNGJKAAPTBOPCF-UHFFFAOYSA-N 0.000 claims description 3
JUSWREQXOXPHMZ-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1N1CCCNCC1 JUSWREQXOXPHMZ-UHFFFAOYSA-N 0.000 claims description 3
DDOXTTNJPLMGEL-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-1-(3-methylbutyl)purine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCC(C)C)C(=O)N(C)C=2N=C1N1CCCNCC1 DDOXTTNJPLMGEL-UHFFFAOYSA-N 0.000 claims description 3
HSKZVLCVTRGJNI-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-1-(5-methylhexyl)purine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCCCC(C)C)C(=O)N(C)C=2N=C1N1CCCNCC1 HSKZVLCVTRGJNI-UHFFFAOYSA-N 0.000 claims description 3
MMTIJDQFBVVAMQ-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-1-(oxolan-2-ylmethyl)purine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CC3OCCC3)C(=O)N(C)C=2N=C1N1CCCNCC1 MMTIJDQFBVVAMQ-UHFFFAOYSA-N 0.000 claims description 3
SHIKPAHPUOTSAR-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-1-phenacylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CC(=O)C=3C=CC=CC=3)C(=O)N(C)C=2N=C1N1CCCNCC1 SHIKPAHPUOTSAR-UHFFFAOYSA-N 0.000 claims description 3
TZRONFORCHMLNM-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-1-propylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1N1CCCNCC1 TZRONFORCHMLNM-UHFFFAOYSA-N 0.000 claims description 3
XNXZBRXFGVBSCN-UHFFFAOYSA-N 7-benzyl-8-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=C(N2C3CC(NC3)C2)N1CC1=CC=CC=C1 XNXZBRXFGVBSCN-UHFFFAOYSA-N 0.000 claims description 3
VEPCEEKGCCWCPJ-UHFFFAOYSA-N 7-benzyl-8-(6,9-diazaspiro[4.5]decan-9-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N(C1)CCNC21CCCC2 VEPCEEKGCCWCPJ-UHFFFAOYSA-N 0.000 claims description 3
KTSVPYMTYULGDU-HXUWFJFHSA-N 7-benzyl-8-[(3r)-3-[(4-fluorophenyl)methyl]piperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CC=C(F)C=C1 KTSVPYMTYULGDU-HXUWFJFHSA-N 0.000 claims description 3
FADGWZGGARZQRH-LJQANCHMSA-N 7-benzyl-8-[(3r)-3-[(4-hydroxyphenyl)methyl]piperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CC=C(O)C=C1 FADGWZGGARZQRH-LJQANCHMSA-N 0.000 claims description 3
LLUHUSTYHAMQBA-HXUWFJFHSA-N 7-benzyl-8-[(3r)-3-[(4-methoxyphenyl)methyl]piperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC(OC)=CC=C1C[C@H]1NCCN(C=2N(C=3C(=O)N(C)C(=O)N(C)C=3N=2)CC=2C=CC=CC=2)C1 LLUHUSTYHAMQBA-HXUWFJFHSA-N 0.000 claims description 3
ANTRLZZSHHSNLE-HXUWFJFHSA-N 7-benzyl-8-[(3r)-3-benzylpiperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CC=CC=C1 ANTRLZZSHHSNLE-HXUWFJFHSA-N 0.000 claims description 3
GWDVHHPRJSAZBM-AWEZNQCLSA-N 7-benzyl-8-[(3s)-3-(hydroxymethyl)piperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCN[C@H](CO)C1 GWDVHHPRJSAZBM-AWEZNQCLSA-N 0.000 claims description 3
ANTRLZZSHHSNLE-FQEVSTJZSA-N 7-benzyl-8-[(3s)-3-benzylpiperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C([C@@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CC=CC=C1 ANTRLZZSHHSNLE-FQEVSTJZSA-N 0.000 claims description 3
XEOACQCALXGGQP-UHFFFAOYSA-N 7-benzyl-8-[3-(hydroxymethyl)-1,4-diazepan-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNC(CO)C1 XEOACQCALXGGQP-UHFFFAOYSA-N 0.000 claims description 3
FXBTVWSOSGLTKO-UHFFFAOYSA-N 7-benzyl-8-[3-[(2-hydroxyphenyl)methyl]piperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N(C1)CCNC1CC1=CC=CC=C1O FXBTVWSOSGLTKO-UHFFFAOYSA-N 0.000 claims description 3
SKJBPVRMHJFCDG-UHFFFAOYSA-N 7-benzyl-8-[3-[(2-methoxyphenyl)methyl]piperazin-1-yl]-1,3-dimethylpurine-2,6-dione Chemical compound COC1=CC=CC=C1CC1NCCN(C=2N(C=3C(=O)N(C)C(=O)N(C)C=3N=2)CC=2C=CC=CC=2)C1 SKJBPVRMHJFCDG-UHFFFAOYSA-N 0.000 claims description 3
XARYHVKQXCTWDU-UHFFFAOYSA-N 7-butyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCCC)C=1N1CCNCC1 XARYHVKQXCTWDU-UHFFFAOYSA-N 0.000 claims description 3
FDYKRGIGKFPKEU-UHFFFAOYSA-N 7-ethyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CC)C=1N1CCNCC1 FDYKRGIGKFPKEU-UHFFFAOYSA-N 0.000 claims description 3
GHMYMBNVKKTJGK-UHFFFAOYSA-N 7-heptyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCCCCCC)C=1N1CCNCC1 GHMYMBNVKKTJGK-UHFFFAOYSA-N 0.000 claims description 3
QGBNTEXAVHATFK-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1,3-dimethyl-7-(2-oxo-2-pyrrolidin-1-ylethyl)purine-2,6-dione Chemical compound C1CCCN1C(=O)CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 QGBNTEXAVHATFK-UHFFFAOYSA-N 0.000 claims description 3
PADMIJHSYFCEFT-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1,3-dimethyl-7-(naphthalen-1-ylmethyl)purine-2,6-dione Chemical compound C=1C=CC2=CC=CC=C2C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 PADMIJHSYFCEFT-UHFFFAOYSA-N 0.000 claims description 3
LNHMCANPHUFGAT-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1,3-dimethyl-7-[(2-methylphenyl)methyl]purine-2,6-dione Chemical compound CC1=CC=CC=C1CN1C(C(=O)N(C)C(=O)N2C)=C2N=C1N1CCNCCC1 LNHMCANPHUFGAT-UHFFFAOYSA-N 0.000 claims description 3
MSDJALZVKJPBHM-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1,3-dimethyl-7-[(2-nitrophenyl)methyl]purine-2,6-dione Chemical compound C=1C=CC=C([N+]([O-])=O)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 MSDJALZVKJPBHM-UHFFFAOYSA-N 0.000 claims description 3
CMHZHZMHFGHPCI-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1,3-dimethyl-7-[[2-(trifluoromethyl)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=CC=C(C(F)(F)F)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 CMHZHZMHFGHPCI-UHFFFAOYSA-N 0.000 claims description 3
RIHCHHSHMVKYMJ-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-(2-ethoxyethyl)-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOCC)C(=O)N(C)C=2N=C1N1CCCNCC1 RIHCHHSHMVKYMJ-UHFFFAOYSA-N 0.000 claims description 3
KVAXGPRMKZKOMP-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-(2-fluoroethyl)-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCF)C(=O)N(C)C=2N=C1N1CCCNCC1 KVAXGPRMKZKOMP-UHFFFAOYSA-N 0.000 claims description 3
QYLRQRANYYXDSZ-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-(2-hydroxypropyl)-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC(O)C)C(=O)N(C)C=2N=C1N1CCCNCC1 QYLRQRANYYXDSZ-UHFFFAOYSA-N 0.000 claims description 3
XQEGWGXBPPWQNU-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-(3-hydroxy-2-methylpropyl)-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC(CO)C)C(=O)N(C)C=2N=C1N1CCCNCC1 XQEGWGXBPPWQNU-UHFFFAOYSA-N 0.000 claims description 3
XWQYLOAJGPLLOH-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-[2-(1,3-dioxolan-2-yl)ethyl]-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCC3OCCO3)C(=O)N(C)C=2N=C1N1CCCNCC1 XWQYLOAJGPLLOH-UHFFFAOYSA-N 0.000 claims description 3
CFNINJAIQCKVJU-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-3-methyl-7-(2-phenylethyl)purine-2,6-dione Chemical compound C=1C=CC=CC=1CCN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 CFNINJAIQCKVJU-UHFFFAOYSA-N 0.000 claims description 3
DWIWTQLAKTVXBM-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-3-methyl-7-[(2-methyl-1,3-thiazol-4-yl)methyl]purine-2,6-dione Chemical compound S1C(C)=NC(CN2C=3C(=O)NC(=O)N(C)C=3N=C2N2CCNCCC2)=C1 DWIWTQLAKTVXBM-UHFFFAOYSA-N 0.000 claims description 3
GWGJFRLRJPHMSY-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-fluorophenyl)methyl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=C(F)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 GWGJFRLRJPHMSY-UHFFFAOYSA-N 0.000 claims description 3
SPSIXCAURMEGQP-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCCNCC1 SPSIXCAURMEGQP-UHFFFAOYSA-N 0.000 claims description 3
JWAGDOQXWWMGQI-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-1-(2-methoxyethyl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOC)C(=O)N(C)C=2N=C1N1CCCNCC1 JWAGDOQXWWMGQI-UHFFFAOYSA-N 0.000 claims description 3
LZCAZOJSGPUTCG-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-1-[(3-methoxyphenyl)methyl]-3-methylpurine-2,6-dione Chemical compound COC1=CC=CC(CN2C(C=3N(CC=4C(=CC=CC=4)I)C(N4CCNCCC4)=NC=3N(C)C2=O)=O)=C1 LZCAZOJSGPUTCG-UHFFFAOYSA-N 0.000 claims description 3
AALWPTUPHRGAQQ-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-1-[2-(2-methoxyethoxy)ethyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOCCOC)C(=O)N(C)C=2N=C1N1CCCNCC1 AALWPTUPHRGAQQ-UHFFFAOYSA-N 0.000 claims description 3
RYNSDHRRCXUHDS-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-3-methyl-1-(2-phenoxyethyl)purine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCOC=3C=CC=CC=3)C(=O)N(C)C=2N=C1N1CCCNCC1 RYNSDHRRCXUHDS-UHFFFAOYSA-N 0.000 claims description 3
WGGDCZLNSXISHJ-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-3-methyl-1-[3-(oxan-2-yloxy)propyl]purine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C1N1CCCNCC1 WGGDCZLNSXISHJ-UHFFFAOYSA-N 0.000 claims description 3
OOJZPGFSLZCGHB-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-3-methyl-1-propylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1N1CCCNCC1 OOJZPGFSLZCGHB-UHFFFAOYSA-N 0.000 claims description 3
PUYLGCCLEODMTE-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 PUYLGCCLEODMTE-UHFFFAOYSA-N 0.000 claims description 3
RQUXMKSKGVLZTG-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-7-[(2-methoxyphenyl)methyl]-1,3-dimethylpurine-2,6-dione Chemical compound COC1=CC=CC=C1CN1C(C(=O)N(C)C(=O)N2C)=C2N=C1N1CCNCCC1 RQUXMKSKGVLZTG-UHFFFAOYSA-N 0.000 claims description 3
XOHFEKGTLDNEFO-UHFFFAOYSA-N methyl 2-(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)-2-phenylacetate Chemical compound C1CNCCN1C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1C(C(=O)OC)C1=CC=CC=C1 XOHFEKGTLDNEFO-UHFFFAOYSA-N 0.000 claims description 3
GOPZBZBOICZBNI-UHFFFAOYSA-N methyl 3-[(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C=3C(=O)N(C)C(=O)N(C)C=3N=C2N2CCNCC2)=C1 GOPZBZBOICZBNI-UHFFFAOYSA-N 0.000 claims description 3
RPDICRQSEPSTAN-UHFFFAOYSA-N methyl 4-[(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]-3-methoxybenzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1CN1C(C(=O)N(C)C(=O)N2C)=C2N=C1N1CCNCC1 RPDICRQSEPSTAN-UHFFFAOYSA-N 0.000 claims description 3
NQMPLCKIYDDBDS-UHFFFAOYSA-N methyl 4-[(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(C(=O)N(C)C(=O)N2C)=C2N=C1N1CCNCC1 NQMPLCKIYDDBDS-UHFFFAOYSA-N 0.000 claims description 3
125000004076 pyridyl group Chemical group 0.000 claims description 3
QSLFJGRSVHGYDS-UHFFFAOYSA-N 3-methyl-7-phenacyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=CC=1C(=O)CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 QSLFJGRSVHGYDS-UHFFFAOYSA-N 0.000 claims description 2
NQOBMESKNSOHRV-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-1-[(3-methoxyphenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound COC1=CC=CC(CN2C(C=3N(CC=4C(=CC=CC=4)I)C(N4CCNCC4)=NC=3N(C)C2=O)=O)=C1 NQOBMESKNSOHRV-UHFFFAOYSA-N 0.000 claims description 2
SKZMGOQYJIYLJU-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-(3-hydroxypropyl)-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1N1CCCNCC1 SKZMGOQYJIYLJU-UHFFFAOYSA-N 0.000 claims description 2
ZZGCNTSOJILLEE-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-1-[2-(1,3-dioxan-2-yl)ethyl]-7-[(2-iodophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CCC3OCCCO3)C(=O)N(C)C=2N=C1N1CCCNCC1 ZZGCNTSOJILLEE-UHFFFAOYSA-N 0.000 claims description 2
MTSZYBPWGIMCNR-UHFFFAOYSA-N 8-(6-benzyl-1,4-diazepan-1-yl)-7-[(2-iodophenyl)methyl]-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N(C1)CCNCC1CC1=CC=CC=C1 MTSZYBPWGIMCNR-UHFFFAOYSA-N 0.000 claims description 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
XFUVREWVWGDRQI-UHFFFAOYSA-N 3-phenacyl-7h-purine-2,6-dione Chemical compound C1=2N=CNC=2C(=O)NC(=O)N1CC(=O)C1=CC=CC=C1 XFUVREWVWGDRQI-UHFFFAOYSA-N 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
238000006467 substitution reaction Methods 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 21
238000004519 manufacturing process Methods 0.000 abstract description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
201000010099 disease Diseases 0.000 abstract description 14
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 14
208000008589 Obesity Diseases 0.000 abstract description 11
235000020824 obesity Nutrition 0.000 abstract description 11
239000008194 pharmaceutical composition Substances 0.000 abstract description 9
102000004169 proteins and genes Human genes 0.000 abstract description 7
108090000623 proteins and genes Proteins 0.000 abstract description 7
230000001225 therapeutic effect Effects 0.000 abstract description 3
229940124639 Selective inhibitor Drugs 0.000 abstract description 2
238000007429 general method Methods 0.000 description 136
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 112
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 111
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 103
238000005160 1H NMR spectroscopy Methods 0.000 description 88
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
238000002360 preparation method Methods 0.000 description 34
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 32
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
239000011541 reaction mixture Substances 0.000 description 25
239000002904 solvent Substances 0.000 description 24
238000011282 treatment Methods 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
239000000203 mixture Substances 0.000 description 23
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
0 CCC(CC1)CCN1c1nc(N(C)C(N(*)C2=*)=O)c2[n]1Cc(cc1)ccc1C1=CSN=*C1 Chemical compound CCC(CC1)CCN1c1nc(N(C)C(N(*)C2=*)=O)c2[n]1Cc(cc1)ccc1C1=CSN=*C1 0.000 description 15
150000001721 carbon Chemical group 0.000 description 15
239000003921 oil Substances 0.000 description 15
235000019198 oils Nutrition 0.000 description 15
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 14
239000000872 buffer Substances 0.000 description 13
239000010410 layer Substances 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 10
229910052760 oxygen Inorganic materials 0.000 description 10
239000000047 product Substances 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000003480 eluent Substances 0.000 description 9
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
229910000041 hydrogen chloride Inorganic materials 0.000 description 9
239000011734 sodium Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 8
239000002585 base Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
206010012601 diabetes mellitus Diseases 0.000 description 8
125000000623 heterocyclic group Chemical group 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
150000004885 piperazines Chemical class 0.000 description 8
MFFGCBDQVBOJBG-UHFFFAOYSA-N 7-benzyl-8-chloro-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=C(Cl)N1CC1=CC=CC=C1 MFFGCBDQVBOJBG-UHFFFAOYSA-N 0.000 description 7
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 7
229910006074 SO2NH2 Inorganic materials 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
229910000027 potassium carbonate Inorganic materials 0.000 description 7
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 7
125000001054 5 membered carbocyclic group Chemical group 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000003472 antidiabetic agent Substances 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000012043 crude product Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000002255 enzymatic effect Effects 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
239000000651 prodrug Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
125000004008 6 membered carbocyclic group Chemical group 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
208000002705 Glucose Intolerance Diseases 0.000 description 5
206010056997 Impaired fasting glucose Diseases 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical class O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 5
201000009104 prediabetes syndrome Diseases 0.000 description 5
238000002953 preparative HPLC Methods 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
229940125708 antidiabetic agent Drugs 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000003826 tablet Substances 0.000 description 4
125000001544 thienyl group Chemical group 0.000 description 4
FAJPYLKQFGMWPX-UHFFFAOYSA-N (1,4-dibenzyl-1,4-diazepan-6-yl)methanol Chemical compound C1CN(CC=2C=CC=CC=2)CC(CO)CN1CC1=CC=CC=C1 FAJPYLKQFGMWPX-UHFFFAOYSA-N 0.000 description 3
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 3
OIXZUXCRAYKHTA-UHFFFAOYSA-N 1,4-diazepan-6-ylmethanol Chemical compound OCC1CNCCNC1 OIXZUXCRAYKHTA-UHFFFAOYSA-N 0.000 description 3
FRZIAMGADODZBX-UHFFFAOYSA-N 1,4-dibenzyl-1,4-diazepan-6-ol Chemical compound C1CN(CC=2C=CC=CC=2)CC(O)CN1CC1=CC=CC=C1 FRZIAMGADODZBX-UHFFFAOYSA-N 0.000 description 3
JYQFYLNTFJXEIF-UHFFFAOYSA-N 1,4-dibenzyl-1,4-diazepane-6-carboxylic acid Chemical compound C1CN(CC=2C=CC=CC=2)CC(C(=O)O)CN1CC1=CC=CC=C1 JYQFYLNTFJXEIF-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010070901 Diabetic dyslipidaemia Diseases 0.000 description 3
108010016626 Dipeptides Proteins 0.000 description 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
229910004373 HOAc Inorganic materials 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
102100040918 Pro-glucagon Human genes 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229940100389 Sulfonylurea Drugs 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
229940123464 Thiazolidinedione Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
125000005002 aryl methyl group Chemical group 0.000 description 3
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
201000006549 dyspepsia Diseases 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
FPLKLNINPXCYAO-UHFFFAOYSA-N methyl 1,4-dibenzyl-1,4-diazepane-2-carboxylate Chemical compound C1CCN(CC=2C=CC=CC=2)C(C(=O)OC)CN1CC1=CC=CC=C1 FPLKLNINPXCYAO-UHFFFAOYSA-N 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000011593 sulfur Chemical group 0.000 description 3
238000010189 synthetic method Methods 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
WWYPEUUJEKQBLS-UHFFFAOYSA-N (1,4-dibenzyl-1,4-diazepan-2-yl)methanol Chemical compound C1CCN(CC=2C=CC=CC=2)C(CO)CN1CC1=CC=CC=C1 WWYPEUUJEKQBLS-UHFFFAOYSA-N 0.000 description 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
UJOAQNJUAPEZLX-UHFFFAOYSA-N 1,4-diazepan-2-ylmethyl acetate Chemical compound CC(=O)OCC1CNCCCN1 UJOAQNJUAPEZLX-UHFFFAOYSA-N 0.000 description 2
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
150000001478 2,5-oxazolidinediones Chemical class 0.000 description 2
BPLFRVBSZYCWQV-UHFFFAOYSA-N 2-[[8-(1,4-diazepan-1-yl)-3-methyl-2,6-dioxopurin-7-yl]methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 BPLFRVBSZYCWQV-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
MBZXPYYVBJVMCQ-UHFFFAOYSA-N 8-(1,4-diazepan-1-yl)-3-methyl-7-phenacylpurine-2,6-dione Chemical compound C=1C=CC=CC=1C(=O)CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCCNCC1 MBZXPYYVBJVMCQ-UHFFFAOYSA-N 0.000 description 2
RYIGNEOBDRVTHA-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2 RYIGNEOBDRVTHA-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
229940123208 Biguanide Drugs 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
229940122199 Insulin secretagogue Drugs 0.000 description 2
229940122355 Insulin sensitizer Drugs 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229910010084 LiAlH4 Inorganic materials 0.000 description 2
208000017170 Lipid metabolism disease Diseases 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000004257 Potassium Channel Human genes 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
229910006069 SO3H Inorganic materials 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
230000036528 appetite Effects 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
235000021229 appetite regulation Nutrition 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
150000004283 biguanides Chemical class 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960004580 glibenclamide Drugs 0.000 description 2
229960000346 gliclazide Drugs 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
229960001381 glipizide Drugs 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
208000002551 irritable bowel syndrome Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
SEGPJFKYVJYBFH-UHFFFAOYSA-N methyl 2-(2-aminopropanoylamino)acetate Chemical class COC(=O)CNC(=O)C(C)N SEGPJFKYVJYBFH-UHFFFAOYSA-N 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000011368 organic material Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
229910000343 potassium bisulfate Inorganic materials 0.000 description 2
108020001213 potassium channel Proteins 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229960002354 repaglinide Drugs 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
230000036186 satiety Effects 0.000 description 2
235000019627 satiety Nutrition 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 2
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000003643 water by type Substances 0.000 description 2
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 1
125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
KIHQZLPHVZKELA-UHFFFAOYSA-N 1,3-dibromopropan-2-ol Chemical compound BrCC(O)CBr KIHQZLPHVZKELA-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
ROHHVEXHMGONRU-UHFFFAOYSA-N 1,4,6-tribenzyl-1,4-diazepane Chemical compound C=1C=CC=CC=1CC(CN(CC=1C=CC=CC=1)CC1)CN1CC1=CC=CC=C1 ROHHVEXHMGONRU-UHFFFAOYSA-N 0.000 description 1
AHQADGZBPLSDCT-UHFFFAOYSA-N 1,4,6-tribenzyl-1,4-diazepane-5,7-dione Chemical compound O=C1N(CC=2C=CC=CC=2)CCN(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 AHQADGZBPLSDCT-UHFFFAOYSA-N 0.000 description 1
UUQDMFIJPQHZFD-UHFFFAOYSA-N 1,4-diazepan-2-ylmethanol Chemical compound OCC1CNCCCN1 UUQDMFIJPQHZFD-UHFFFAOYSA-N 0.000 description 1
SJLSQITZGUTOMN-UHFFFAOYSA-N 1,4-diazepan-6-ol Chemical compound OC1CNCCNC1 SJLSQITZGUTOMN-UHFFFAOYSA-N 0.000 description 1
YTRPKDXWJSGDKS-UHFFFAOYSA-N 1,4-dibenzyl-1,4-diazepane-5,7-dione Chemical compound C1CN(CC=2C=CC=CC=2)C(=O)CC(=O)N1CC1=CC=CC=C1 YTRPKDXWJSGDKS-UHFFFAOYSA-N 0.000 description 1
APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
KMZQRUPUJWTKOJ-GOSISDBHSA-N 2-[[1,3-dimethyl-2,6-dioxo-8-[(3r)-3-(thiophen-2-ylmethyl)piperazin-1-yl]purin-7-yl]methyl]benzonitrile Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C(=CC=CC=1)C#N)=O)C)C1=CC=CS1 KMZQRUPUJWTKOJ-GOSISDBHSA-N 0.000 description 1
ATQGSDYBRSUYDT-UHFFFAOYSA-N 2-[[7-benzyl-8-(1,4-diazepan-1-yl)-3-methyl-2,6-dioxopurin-1-yl]methyl]benzonitrile Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CC=3C(=CC=CC=3)C#N)C(=O)N(C)C=2N=C1N1CCCNCC1 ATQGSDYBRSUYDT-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
QHNLUOLQHACRMA-UHFFFAOYSA-N 3-benzyl-7-[(2-iodophenyl)methyl]-8-piperazin-1-yl-1-propylpurine-2,6-dione Chemical compound C1=2N=C(N3CCNCC3)N(CC=3C(=CC=CC=3)I)C=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 QHNLUOLQHACRMA-UHFFFAOYSA-N 0.000 description 1
WZSVWBHQCKANJC-UHFFFAOYSA-N 3-benzyl-8-bromo-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(Br)=NC=2N1CC1=CC=CC=C1 WZSVWBHQCKANJC-UHFFFAOYSA-N 0.000 description 1
QQZJWQCLWOQDQV-UHFFFAOYSA-N 3-bromo-2-(bromomethyl)propanoic acid Chemical compound OC(=O)C(CBr)CBr QQZJWQCLWOQDQV-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
IWKDPLLNUIDGOF-UHFFFAOYSA-N 4-[(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)methyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1N1CCNCC1 IWKDPLLNUIDGOF-UHFFFAOYSA-N 0.000 description 1
FFRYEFLPFGXVSV-OAQYLSRUSA-N 4-[[(2r)-4-(7-benzyl-1,3-dimethyl-2,6-dioxopurin-8-yl)piperazin-2-yl]methyl]benzonitrile Chemical compound C([C@H]1NCCN(C1)C1=NC=2N(C(N(C)C(=O)C=2N1CC=1C=CC=CC=1)=O)C)C1=CC=C(C#N)C=C1 FFRYEFLPFGXVSV-OAQYLSRUSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical compound C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
YUCGPEKPTLIAMT-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-yl-1-[[3-(trifluoromethoxy)phenyl]methyl]purine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)N(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)N(C)C=2N=C1N1CCNCC1 YUCGPEKPTLIAMT-UHFFFAOYSA-N 0.000 description 1
HBJFRCIMFSKUQJ-UHFFFAOYSA-N 7-[(2-iodophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(I)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 HBJFRCIMFSKUQJ-UHFFFAOYSA-N 0.000 description 1
CMBGVCOANBXXBH-UHFFFAOYSA-N 7-benzyl-1-(2-cyclohexylethyl)-8-(1,4-diazepan-1-yl)-3-methylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCC3CCCCC3)C(=O)N(C)C=2N=C1N1CCCNCC1 CMBGVCOANBXXBH-UHFFFAOYSA-N 0.000 description 1
RGJWYPAWXHIEGX-UHFFFAOYSA-N 7-benzyl-8-(3,5-dimethylpiperazin-1-yl)-1,3-dimethylpurine-2,6-dione Chemical compound C1C(C)NC(C)CN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(C)C(=O)N2C RGJWYPAWXHIEGX-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
QTEQVEJOXGBDGI-UHFFFAOYSA-N 8-bromo-3-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1NC(Br)=N2 QTEQVEJOXGBDGI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
PBNRMIRYFYSTEN-UHFFFAOYSA-N C=CC(c1c(C[n]2c(N3CCCCC3)nc(N(Cc3ccccc3)C(N3)=O)c2C3=O)cccc1)(F)F Chemical compound C=CC(c1c(C[n]2c(N3CCCCC3)nc(N(Cc3ccccc3)C(N3)=O)c2C3=O)cccc1)(F)F PBNRMIRYFYSTEN-UHFFFAOYSA-N 0.000 description 1
125000006519 CCH3 Chemical group 0.000 description 1
DCPDQAPUJVDJRX-UHFFFAOYSA-N CN(c1c(C(N2)=O)[n](Cc(cccc3)c3C3=CCCC=C3)c(N3CCNCCC3)n1)C2=O Chemical compound CN(c1c(C(N2)=O)[n](Cc(cccc3)c3C3=CCCC=C3)c(N3CCNCCC3)n1)C2=O DCPDQAPUJVDJRX-UHFFFAOYSA-N 0.000 description 1
YGRGGZZTUSFWJJ-UHFFFAOYSA-N CN(c1c(C(N2C)=O)[n](CCCC#N)c(CCC3CCNCC3)n1)C2=O Chemical compound CN(c1c(C(N2C)=O)[n](CCCC#N)c(CCC3CCNCC3)n1)C2=O YGRGGZZTUSFWJJ-UHFFFAOYSA-N 0.000 description 1
LJOYDPVOERYVGQ-UHFFFAOYSA-N CN(c1c(C(N2C)=O)[n](Cc(cccc3)c3Br)c(NCCCN)n1)C2=O Chemical compound CN(c1c(C(N2C)=O)[n](Cc(cccc3)c3Br)c(NCCCN)n1)C2=O LJOYDPVOERYVGQ-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
101710092928 Insulin-like peptide-1 Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
244000025272 Persea americana Species 0.000 description 1
235000008673 Persea americana Nutrition 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
NJVHJTQSGGRHGP-UHFFFAOYSA-K [Li].[Al+3].[Cl-].[Cl-].[Cl-] Chemical compound [Li].[Al+3].[Cl-].[Cl-].[Cl-] NJVHJTQSGGRHGP-UHFFFAOYSA-K 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
238000009835 boiling Methods 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
229950009226 ciglitazone Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019138 food restriction Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
239000003316 glycosidase inhibitor Substances 0.000 description 1
108010077515 glycylproline Proteins 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000002473 insulinotropic effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000005921 isopentoxy group Chemical group 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
ROXQOUUAPQUMLN-UHFFFAOYSA-N methyl 2,3-dibromopropanoate Chemical compound COC(=O)C(Br)CBr ROXQOUUAPQUMLN-UHFFFAOYSA-N 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
KXBUDXGDASOGBX-UHFFFAOYSA-N n',n'-dibenzylpropane-1,3-diamine Chemical compound C=1C=CC=CC=1CN(CCCN)CC1=CC=CC=C1 KXBUDXGDASOGBX-UHFFFAOYSA-N 0.000 description 1
125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229960000698 nateglinide Drugs 0.000 description 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008289 pathophysiological mechanism Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
239000004036 potassium channel stimulating agent Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000012622 synthetic inhibitor Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
150000005671 trienes Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000008096 xylene Substances 0.000 description 1
238000013293 zucker diabetic fatty rat Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2002507812A 2000-07-04 2001-07-04 酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物 Withdrawn JP2004502690A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200001040		2000-07-04
US22324000P	2000-08-04	2000-08-04
PCT/DK2001/000467 WO2002002560A2 (en)	2000-07-04	2001-07-04	Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)

Publications (2)

Publication Number	Publication Date
JP2004502690A true JP2004502690A (ja)	2004-01-29
JP2004502690A5 JP2004502690A5 (2)	2005-02-03

Family

ID=26068848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002507812A Withdrawn JP2004502690A (ja)	2000-07-04	2001-07-04	酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物

Country Status (8)

Country	Link
US (2)	US20020161001A1 (2)
EP (1)	EP1301187B1 (2)
JP (1)	JP2004502690A (2)
AU (2)	AU2001268958B2 (2)
HU (1)	HUP0301622A3 (2)
MX (1)	MXPA02012272A (2)
PL (1)	PL360856A1 (2)
WO (1)	WO2002002560A2 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008247911A (ja) *	2001-02-24	2008-10-16	Boehringer Ingelheim Pharma Gmbh & Co Kg	キサンチン誘導体、それらの調製及び医薬組成物としてのそれらの使用
JP2018522862A (ja) *	2015-06-25	2018-08-16	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	キサンチンをベースとする化合物の調製方法

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US20040152745A1 (en) *	1999-11-12	2004-08-05	Guilford Pharmaceuticals, Inc.	Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
ES2257555T3 (es)	2001-06-20	2006-08-01	MERCK & CO., INC.	Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
CA2450579A1 (en)	2001-06-20	2003-01-03	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP4357293B2 (ja)	2001-06-27	2009-11-04	スミスクラインビーチャムコーポレーション	ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
CN1723196A (zh)	2001-06-27	2006-01-18	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
ATE380175T1 (de)	2001-06-27	2007-12-15	Smithkline Beecham Corp	Pyrrolidine als dipeptidyl peptidase inhibitoren
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DE60225556D1 (de) *	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002331311A1 (en) *	2001-09-19	2003-04-01	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US20070197552A1 (en) *	2002-01-11	2007-08-23	Novo Nordisk A/S	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
EP1338595B1 (en) *	2002-02-25	2006-05-03	Eisai Co., Ltd.	Xanthine derivatives as DPP-IV inhibitors
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
DE60307628T2 (de) *	2002-05-31	2007-08-09	Schering Corporation	Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
AU2003241960B2 (en)	2002-06-06	2009-07-30	Eisai R&D Management Co., Ltd.	Novel fused imidazole derivative
WO2004009091A1 (en)	2002-06-17	2004-01-29	Glaxo Group Limited	Purine derivatives as liver x receptor agonists
US7208498B2 (en)	2002-07-15	2007-04-24	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
ES2339112T3 (es) *	2002-08-21	2010-05-17	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG	8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) *	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7495005B2 (en)	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en)	2002-08-22	2009-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10238470A1 (de) *	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2003262059A1 (en) *	2002-09-11	2004-04-30	Takeda Pharmaceutical Company Limited	Sustained release preparation
MXPA05003252A (es) *	2002-09-26	2005-07-05	Eisai Co Ltd	Farmaco de combinacion.
ATE370141T1 (de)	2002-10-07	2007-09-15	Merck & Co Inc	Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
AU2003269850A1 (en) *	2002-10-08	2004-05-04	Novo Nordisk A/S	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
CA2502269C (en)	2002-10-18	2009-12-22	Merck & Co., Inc.	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2003280680A1 (en) *	2002-11-01	2004-06-18	Sumitomo Pharmaceuticals Co., Ltd.	Xanthine compound
CA2504735C (en)	2002-11-07	2009-06-23	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7482337B2 (en)	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) *	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7109192B2 (en)	2002-12-03	2006-09-19	Boehringer Ingelheim Pharma Gmbh & Co Kg	Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (es) *	2002-12-03	2004-06-30	Boehringer Ingelheim Pharma	Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
EP1589969A4 (en)	2003-01-17	2008-08-13	Merck & Co Inc	3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CA2513684A1 (en)	2003-01-31	2004-08-19	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2518465A1 (en) *	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
EP1961416B1 (en)	2003-05-05	2013-01-23	Probiodrug AG	Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
CN1784220B (zh)	2003-05-05	2011-08-03	前体生物药物股份公司	谷氨酰胺酰基和谷氨酸环化酶效应物的应用
WO2004098591A2 (en)	2003-05-05	2004-11-18	Probiodrug Ag	Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
US7560455B2 (en)	2003-05-14	2009-07-14	Merck & Co., Inc.	3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
CN1798556A (zh)	2003-06-06	2006-07-05	麦克公司	作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
CN1809544A (zh)	2003-06-17	2006-07-26	麦克公司	作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物
DE10327439A1 (de) *	2003-06-18	2005-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en)	2003-06-18	2009-07-28	Boehringer Ingelheim International Gmbh	Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7259160B2 (en)	2003-07-31	2007-08-21	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8921311B2 (en)	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
US9078866B2 (en) *	2003-08-01	2015-07-14	Mannkind Corporation	Method for treating hyperglycemia with GLP-1
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1659123A1 (en) *	2003-08-29	2006-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic pyrazole derivative
EP1699777B1 (en)	2003-09-08	2012-12-12	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1697342A2 (en) *	2003-09-08	2006-09-06	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
BRPI0415409A (pt)	2003-10-15	2006-12-05	Probiodrug Ag	uso de efetuadores de ciclases de glutaminila e glutamato
AU2004290499C1 (en)	2003-11-03	2011-02-24	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
WO2005049022A2 (en)	2003-11-17	2005-06-02	Novartis Ag	Use of dipeptidyl peptidase iv inhibitors
DE10355304A1 (de)	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070219178A1 (en) *	2003-12-04	2007-09-20	Eisai Co., Ltd.	Preventive or therapeutic agents for multiple sclerosis
DE10359098A1 (de) *	2003-12-17	2005-07-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
US7217711B2 (en)	2003-12-17	2007-05-15	Boehringer Ingelheim International Gmbh	Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
CA2554809C (en)	2004-02-05	2014-04-29	Probiodrug Ag	Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1758905B1 (de)	2004-02-18	2009-04-29	Boehringer Ingelheim International GmbH	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
DE102004009039A1 (de)	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7393847B2 (en)	2004-03-13	2008-07-01	Boehringer Ingleheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
UA85871C2 (uk)	2004-03-15	2009-03-10	Такеда Фармасьютікал Компані Лімітед	Інгібітори дипептидилпептидази
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
WO2005108382A1 (en)	2004-05-04	2005-11-17	Merck & Co., Inc.	1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7439370B2 (en)	2004-05-10	2008-10-21	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
WO2005116029A1 (en)	2004-05-18	2005-12-08	Merck & Co., Inc.	Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7842707B2 (en) *	2004-07-23	2010-11-30	Nuada, Llc	Peptidase inhibitors
DE102004038270A1 (de) *	2004-08-06	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038268A1 (de) *	2004-08-06	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
DE102004043944A1 (de)	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de)	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AU2006215041B2 (en)	2005-02-18	2012-05-31	Mitsubishi Tanabe Pharma Corporation	Salt of proline derivative, solvate thereof, and production method thereof
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
FR2889189A1 (fr) *	2005-07-28	2007-02-02	Cerep Sa	Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MY147393A (en) *	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
PT1931350E (pt) *	2005-09-14	2014-02-12	Takeda Pharmaceutical	Administração de inibidores de dipeptidil peptidase
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
KR100792275B1 (ko) *	2006-02-22	2008-01-08	영진약품공업주식회사	베타아미노기를 갖는 고리화된 히드라자이드 유도체, 이의 약학적으로 허용 가능한 염 및 이의 제조 방법
IN2015DN00888A (2)	2006-02-22	2015-07-10	Mannkind Corp
WO2007112368A1 (en) *	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7833730B2 (en)	2006-04-11	2010-11-16	Arena Pharmaceuticals, Inc.	Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
AU2007235876A1 (en)	2006-04-12	2007-10-18	Probiodrug Ag	Enzyme inhibitors
EP1852108A1 (en) *	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
JP2010500326A (ja)	2006-08-08	2010-01-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
MX2009002772A (es) *	2006-09-13	2009-05-28	Takeda Pharmaceutical	Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (de)	2006-11-30	2012-05-15	Probiodrug Ag	Neue inhibitoren von glutaminylcyclase
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
EP2142514B1 (en)	2007-04-18	2014-12-24	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
WO2009024542A2 (en) *	2007-08-17	2009-02-26	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
JP2011500850A (ja) *	2007-10-24	2011-01-06	マンカインドコーポレイション	Ｇｌｐ−１による副作用を防止する方法
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
NZ604091A (en) *	2008-08-15	2014-08-29	Boehringer Ingelheim Int	Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP5934645B2 (ja)	2009-09-11	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
JP6026284B2 (ja)	2010-03-03	2016-11-16	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤
NZ602312A (en)	2010-03-10	2014-02-28	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
CA2795513A1 (en)	2010-04-06	2011-10-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
EP3323818A1 (en)	2010-09-22	2018-05-23	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP2686313B1 (en)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
WO2015003881A1 (en) *	2013-07-08	2015-01-15	Syngenta Participations Ag	Microbiocidal heterobicyclic derivatives
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
JP2020515639A (ja)	2017-04-03	2020-05-28	コヒラス・バイオサイエンシズ・インコーポレイテッド	進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT313916B (de) *	1971-10-28	1974-03-11	Degussa	Verfahren zur Herstellung von neuen basisch substituierten Theophyllinen und deren Säureadditionssalzen
US4719245A (en) *	1984-03-08	1988-01-12	The Dow Chemical Company	Flexible polyisocyanurate-urethane foam
US4636229A (en) *	1984-03-26	1987-01-13	Nippon Oil Company, Limited	Selective gas separation membrane
FR2654935B1 (fr) *	1989-11-28	1994-07-01	Lvmh Rech	Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9020959D0 (en) *	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
FR2668150B1 (fr) *	1990-10-17	1994-11-18	Theramex	Nouveaux derives du terbutylphenyl 1-amino 4-hydroxybutane, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6011155A (en)	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP2583675A1 (en)	1998-02-02	2013-04-24	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6815446B1 (en) *	1999-08-31	2004-11-09	Vanderbilt University	Selective antagonists of A2B adenosine receptors
EP1368349B1 (de) *	2001-02-24	2007-02-14	Boehringer Ingelheim Pharma GmbH & Co.KG	Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE520694T1 (de) *	2001-11-09	2011-09-15	Gilead Palo Alto Inc	A2b-adenosinrezeptorantagonisten
EP1338595B1 (en) *	2002-02-25	2006-05-03	Eisai Co., Ltd.	Xanthine derivatives as DPP-IV inhibitors
AU2003241960B2 (en) *	2002-06-06	2009-07-30	Eisai R&D Management Co., Ltd.	Novel fused imidazole derivative
US7879316B2 (en) *	2002-06-12	2011-02-01	L'oreal	Cosmetic composition containing a polyorganosiloxane polymer
FR2841346B1 (fr) *	2002-06-19	2004-11-05	Eastman Kodak Co	Procede de developpement d'un produit photographique a haut contraste contenant un agent de nucleation de type polyhydrazide

2001
- 2001-07-04 AU AU2001268958A patent/AU2001268958B2/en not_active Expired - Fee Related
- 2001-07-04 HU HU0301622A patent/HUP0301622A3/hu unknown
- 2001-07-04 MX MXPA02012272A patent/MXPA02012272A/es active IP Right Grant
- 2001-07-04 PL PL01360856A patent/PL360856A1/xx not_active Application Discontinuation
- 2001-07-04 AU AU6895801A patent/AU6895801A/xx active Pending
- 2001-07-04 JP JP2002507812A patent/JP2004502690A/ja not_active Withdrawn
- 2001-07-04 WO PCT/DK2001/000467 patent/WO2002002560A2/en not_active Ceased
- 2001-07-04 EP EP01947211A patent/EP1301187B1/en not_active Expired - Lifetime
- 2001-08-22 US US09/935,149 patent/US20020161001A1/en not_active Abandoned
2003
- 2003-07-17 US US10/621,302 patent/US7235538B2/en not_active Expired - Fee Related

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008247911A (ja) *	2001-02-24	2008-10-16	Boehringer Ingelheim Pharma Gmbh & Co Kg	キサンチン誘導体、それらの調製及び医薬組成物としてのそれらの使用
JP2012121908A (ja) *	2001-02-24	2012-06-28	Boehringer Ingelheim Pharma Gmbh & Co Kg	キサンチン誘導体、それらの調製及び医薬組成物としてのそれらの使用
JP2018522862A (ja) *	2015-06-25	2018-08-16	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	キサンチンをベースとする化合物の調製方法

Also Published As

Publication number	Publication date
WO2002002560A3 (en)	2002-04-25
HUP0301622A3 (en)	2006-05-29
AU6895801A (en)	2002-01-14
AU2001268958B2 (en)	2006-03-09
WO2002002560A2 (en)	2002-01-10
US20020161001A1 (en)	2002-10-31
MXPA02012272A (es)	2003-04-25
EP1301187A2 (en)	2003-04-16
US7235538B2 (en)	2007-06-26
HUP0301622A2 (hu)	2003-09-29
PL360856A1 (en)	2004-09-20
EP1301187B1 (en)	2005-07-06
US20040034014A1 (en)	2004-02-19

Legal Events

Date

Code

Title

Description

2008-06-11

A621

Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080610

2008-07-05

A761

Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080704

Publication	Publication Date	Title
JP2004502690A (ja)	2004-01-29	酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物
AU2001268958A1 (en)	2002-04-11	Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
US20030199528A1 (en)	2003-10-23	Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
US7192952B2 (en)	2007-03-20	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1496877B1 (en)	2008-10-01	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
EP1404675B1 (en)	2008-03-12	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US7074798B2 (en)	2006-07-11	Xanthine derivative and DPPIV inhibitor
RU2318824C2 (ru)	2008-03-10	Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
JP4800964B2 (ja)	2011-10-26	肥満症の治療においてグルコキナーゼ活性化剤として使用するための、ヘテロアリールインドールカルボキサミドおよびその類似体
WO2004033455A2 (en)	2004-04-22	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US7795269B2 (en)	2010-09-14	A2B adenosine receptor antagonists
US20030229106A1 (en)	2003-12-11	A2B adenosine receptor antagonists
JP2003520849A (ja)	2003-07-08	酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン
EP1092435B1 (en)	2007-04-04	Remedies for diabetes
US7304070B2 (en)	2007-12-04	A2B adenosine receptor antagonists
CA2524778A1 (en)	2004-12-09	Xanthine derivatives as a2b adenosine receptor antagonists
US20070197552A1 (en)	2007-08-23	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
ES2244634T3 (es)	2005-12-16	Purina-2,6-dionas como inhibidoras de la enzima dipeptidil peptidasa iv (ddp-iv).
RU2318825C2 (ru)	2008-03-10	Производные ксантина в качестве антагонистов a2b аденозинового рецептора